Aldeyra Therapeutics, Inc.

DB:137 Stock Report

Market Cap: €278.7m

Aldeyra Therapeutics Valuation

Is 137 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 137 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 137 (€4.64) is trading below our estimate of fair value (€26.52)

Significantly Below Fair Value: 137 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 137?

Key metric: As 137 is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 137. This is calculated by dividing 137's market cap by their current book value.
What is 137's PB Ratio?
PB Ratio3.5x
BookUS$85.10m
Market CapUS$294.18m

Price to Book Ratio vs Peers

How does 137's PB Ratio compare to its peers?

The above table shows the PB ratio for 137 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average1.9x
HPHA Heidelberg Pharma
3.1x-33.0%€110.9m
FYB Formycon
1.5x32.4%€882.8m
2INV 2invest
1xn/a€64.4m
BIO3 Biotest
2x29.3%€1.3b
137 Aldeyra Therapeutics
3.5x71.6%€294.2m

Price-To-Book vs Peers: 137 is expensive based on its Price-To-Book Ratio (3.5x) compared to the peer average (1.9x).

Price to Book Ratio vs Industry

How does 137's PB Ratio compare vs other companies in the DE Biotechs Industry?

3 CompaniesPrice / BookEstimated GrowthMarket Cap
V9Z Aceragen
0.1xn/aUS$3.12m
V9Z Aceragen
0.1xn/aUS$2.18m
O7P NeuBase Therapeutics
0.1xn/aUS$1.39m
No more companies available in this PB range
137 3.5xIndustry Avg. 2.4xNo. of Companies3PB00.61.21.82.43+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: 137 is expensive based on its Price-To-Book Ratio (3.5x) compared to the European Biotechs industry average (2.4x).

Price to Book Ratio vs Fair Ratio

What is 137's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

137 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio3.5x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 137's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 137 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€4.64
€9.60
+107.2%
13.2%€11.52€7.68n/a8
Nov ’25€4.83
€9.16
+89.6%
13.2%€10.99€7.33n/a8
Oct ’25€4.79
€9.16
+91.3%
13.2%€10.99€7.33n/a8
Sep ’25€4.81
€9.16
+90.4%
13.2%€10.99€7.33n/a8
Aug ’25€3.61
€8.49
+135.4%
16.9%€10.10€6.43n/a8
Jul ’25€3.05
€8.49
+178.4%
16.9%€10.10€6.43n/a8
Jun ’25€3.41
€8.65
+153.4%
16.9%€10.28€6.54n/a8
May ’25€3.75
€8.65
+130.8%
16.9%€10.28€6.54n/a8
Apr ’25€3.25
€8.71
+168.3%
17.3%€10.20€6.49n/a5
Mar ’25€3.32
€8.59
+158.5%
17.3%€10.05€6.40n/a5
Feb ’25€2.89
€8.59
+197.6%
17.3%€10.05€6.40n/a5
Jan ’25€3.22
€8.56
+166.3%
17.3%€10.02€6.38n/a5
Dec ’24€2.52
€8.56
+239.8%
17.3%€10.01€6.37n/a5
Nov ’24€2.36
€11.36
+381.2%
22.4%€14.19€7.57€4.835
Oct ’24€5.96
€18.72
+214.1%
32.9%€27.49€12.83€4.797
Sep ’24€6.83
€18.72
+174.3%
32.9%€27.49€12.83€4.817
Aug ’24€7.31
€18.72
+156.3%
32.9%€27.49€12.83€3.617
Jul ’24€7.42
€18.72
+152.5%
32.9%€27.49€12.83€3.057
Jun ’24€8.82
€18.99
+115.4%
33.1%€27.88€12.08€3.417
May ’24€8.13
€19.60
+141.2%
34.1%€28.19€12.22€3.757
Apr ’24€8.64
€19.60
+126.9%
34.1%€28.19€12.22€3.257
Mar ’24€6.32
€19.37
+206.3%
32.8%€28.84€12.50€3.327
Feb ’24€5.36
€19.37
+261.2%
32.8%€28.84€12.50€2.897
Jan ’24€6.58
€19.37
+194.5%
32.8%€28.84€12.50€3.227
Dec ’23€5.30
€19.37
+265.1%
32.8%€28.84€12.50€2.527
Nov ’23€5.49
€21.00
+282.4%
33.4%€30.62€13.27€2.367

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Aspen Pharmacare Holdings

R73.7b

Manufactures and supplies specialty and branded pharmaceutical products worldwide.

LDZA

R8.60

7D

-3.9%

1Y

-0.6%

Collegium Pharmaceutical

US$990.4m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

354

US$29.00

7D

1.4%

1Y

25.0%

Pharming Group

€492.8m

A biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally.

PHGN

€0.72

7D

-1.0%

1Y

-31.3%